Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
about
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysisEffects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetesSafe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trialEffect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).The effect of SGLT2 inhibitors on cardiovascular events and renal function.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.SGLT2 Inhibitors: Benefit/Risk Balance.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.A Case of Septic Shock Due to Serratia marcescens Pyelonephritis and Bacteremia in a Patient Receiving Empagliflozin.Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UKCombination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus.Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus.An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin.Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.SGLT2 inhibitors: are they safe?Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study.Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
P2860
Q26740253-0F635708-2B19-4499-A9BE-F2347B54CA27Q28553482-46E7E7FD-EF0F-4F57-B48B-E26D3B0EE557Q33767478-6B5D1600-6527-424F-BBF4-8E345C356640Q33845734-92081ED9-1C19-4C7E-835D-30F9BD9FC9E0Q33887783-9FAE275A-2326-41B3-A7AD-ACBE23417A34Q36179371-5679690D-6B27-452D-962F-EAC998D6B9B7Q37130563-7A55E252-AC8F-469F-8433-E336D0798A17Q37310483-93391ED9-AC96-4DF7-8F94-9D20C2CFE7DFQ37561260-400E74C8-AF68-463A-9172-4147B3CA27F2Q37588847-AF6224CA-0C05-4ADB-9090-9B64316A62A3Q37712199-D1184D63-C04F-49DA-B9A1-61E103BF39DDQ37736727-AEAEB99F-1E09-476B-9310-B4395C0FCA11Q38371417-1B4BDF30-6BE7-4E69-A8B5-D43788B712D4Q38614488-4F7C596F-8269-4703-8AF6-3BDDA5C6BC7BQ38856808-287223B6-9C58-4B5F-96D6-AE7835D10454Q38902321-180B1139-0CA3-4F28-A8E8-DC7E4076B9B5Q38931842-19461516-2CED-45FB-AAA3-66E767EFF0B6Q39000587-2F29CAC5-1D5E-404A-834E-144A8F6FB8E2Q39013664-F4BD571C-8382-41E1-985F-B08C3371D545Q39063447-67C31669-E58D-4235-B499-BCE0349D63D0Q39170860-5E0DF07C-4744-4C59-A7A5-DDBFB5B7ACC5Q39190208-80C68BE8-B160-4AA4-9B9A-11F270AC44DDQ39231122-95A96E4E-0A09-4CC1-911C-91257F52D52FQ39290337-3742B733-67A2-4EB0-8EA4-F35C6BD18A54Q39309680-B0BDC75B-89F7-4B8E-A47F-637F64B2E369Q40068172-18CAEBED-2D5E-4464-A380-1095EF77D285Q40439768-9AB696AB-0D9A-41F8-9776-6871A001F579Q40445386-09BB6100-A16A-4E68-98D0-E91E405A372FQ40550581-366F0EB2-F1A2-45E9-82F2-3AB53066A1FFQ41258175-D8E16118-48DD-4714-A07F-86DBA80B8533Q42371759-B58F1F85-9760-4173-87BA-C9FAC8C15C8CQ46087999-CAA66BBA-9ADA-4160-8E36-EA0D07A540FDQ46184005-4718B7E9-C0E1-4E94-BCB4-991B75E055F3Q47174001-791A9519-0D75-428D-ACF5-2106D9C9EDBAQ47367638-DF776242-B927-41B7-AE82-23DC486C39D8Q47642298-98CCF984-211F-4C4E-91D4-3811B20F7171Q47687852-F6B1A865-4583-421B-A799-562A1FEEBE4DQ47918474-AC8FCFE2-2421-4D96-80A7-7BD45E07392BQ48264817-FCD844F1-9438-4F8C-9852-5D5492F8B199Q49473968-54111C6B-3A48-4B94-962A-726F4158A153
P2860
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Efficacy and safety of sodium- ...... iew and network meta-analysis.
@en
type
label
Efficacy and safety of sodium- ...... iew and network meta-analysis.
@en
prefLabel
Efficacy and safety of sodium- ...... iew and network meta-analysis.
@en
P2093
P2860
P356
P1476
Efficacy and safety of sodium- ...... view and network meta-analysis
@en
P2093
P2860
P304
P356
10.1111/DOM.12670
P577
2016-05-13T00:00:00Z